Literature DB >> 3738760

Bile inhibits release of cholecystokinin and neurotensin.

G Gomez, F Lluis, Y S Guo, G H Greeley, C M Townsend, J C Thompson.   

Abstract

We have investigated the effect of bile on fat-stimulated release and basal plasma levels of cholecystokinin-33/39 (CCK) and neurotensin in six awake dogs prepared with chronic gastric and duodenal cannulas. Experimental bile diversion was achieved by catheterization of the common bile duct through the duodenal cannula; the gallbladder was undisturbed. Bile diversion significantly enhanced the release of both CCK and neurotensin that was stimulated by intraduodenal (ID) infusion of a triglyceride suspension (corn oil) (0.5 gm/kg-hr). The integrated release with ID triglyceride (ng [0 to 90 min]/ml) for CCK was control 5.58 +/- 0.83, bile diversion 14.47 +/- 2.81, bile excess 1.68 +/- 0.56, and for neurotensin was control 0.35 +/- 0.19, bile diversion 1.26 +/- 0.35, and bile excess 0.45 +/- 0.31. ID infusion of excessive bile (bile collected during bile diversion) significantly inhibited both the release and basal levels of CCK. Bile diversion alone did not modify plasma levels of CCK or neurotensin. We conclude that: endogenous bile exerts a negative feedback effect on release of CCK and neurotensin induced by triglyceride and on basal plasma levels of CCK; bile is unnecessary for the stimulation of endocrine cells in the intestinal mucosa by dietary fat; and measured basal levels of CCK and neurotensin represent a real amount of circulating peptide in the fasting state, that is, the basal levels are real and not artifactual.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3738760

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

Review 1.  Biliary motility.

Authors:  P A Grace; G J Poston; R C Williamson
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

2.  Chronic diversion of bile to the urinary bladder induces pancreatic growth in dogs.

Authors:  M Takahashi; I Sasaki; H Naito; Y Funayama; C Shibata; N Ohtani; S Matsuno
Journal:  J Gastrointest Surg       Date:  2000 Sep-Oct       Impact factor: 3.452

3.  Effect of cholestyramine and cholecystokinin receptor antagonist CR1505 (loxiglumide) on lower esophageal sphincter pressure in man.

Authors:  A A Masclee; J B Jansen; L C Rovati; C B Lamers
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

4.  Luminal bile regulates cholecystokinin release in conscious rats.

Authors:  R Nakamura; K Miyasaka; Y Kuyama; K Kitani
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

5.  Dissociation of cholecystokinin and pancreaticobiliary response to intraduodenal bile acids and cholestyramine in humans.

Authors:  I Koop; S Dorn; H Koop; S Witzleb; C Beglinger; A Schafmayer; R Arnold
Journal:  Dig Dis Sci       Date:  1991-11       Impact factor: 3.199

6.  Correlation of cholecystokinin receptors with gallbladder contractility in patients with gallstones.

Authors:  J R Upp; W H Nealon; P Singh; C J Fagan; A S Jonas; G H Greeley; J C Thompson
Journal:  Ann Surg       Date:  1987-06       Impact factor: 12.969

7.  The influence of bile acids on the regulation of exocrine pancreatic secretion and on the plasma concentrations of neurotensin and CCK in dogs.

Authors:  R Nustede; W E Schmidt; H Köhler; U R Fölsch; A Schafmayer
Journal:  Int J Pancreatol       Date:  1993-02

8.  Direct, concentration-dependent inhibition by taurocholate of pancreatic exocrine secretion and CCK release in conscious rats.

Authors:  H Tomita; K Miyasaka; M Matsumoto; A Funakoshi
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

9.  Bile acids in human plasma interfere with cholecystokinin bioassay using dispersed pancreatic acini.

Authors:  K Miyasaka; A Funakoshi; M Matsumoto; R Nakamura; S Sakamoto; H Sakai; K Kitani
Journal:  Dig Dis Sci       Date:  1991-03       Impact factor: 3.199

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.